Arbutus Biopharma Corporation (ABUS) Key Metrics
ABUS valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $646.8M
- Enterprise value
- $868.7M
- P/E (TTM)
- 5.3
- Forward P/E
- 10.2
- PEG ratio
- —
- Price / sales
- 3.6 10-yr median 36.8
- Price / book
- 3.8 10-yr median 2.5
- EV / EBITDA
- 5.9
- Dividend yield
- —
- Beta
- 0.76
ABUS key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsABUS valuation Price multiples at each fiscal year-end price.
Price / sales−33.5%
65.4
2025 · hover or tap a bar for each year
20162025
Price / book+93.1%
12.0
2025 · hover or tap a bar for each year
20162025
Free cash flow yield+6.4 pts
−4.3%
2025 · hover or tap a bar for each year
20162025
ABUS returns How much profit the business earns on the capital it uses.
Return on equity+30.2 pts
−38.5%
2025 · hover or tap a bar for each year
20162025
Return on assets+21.0 pts
−29.6%
2025 · hover or tap a bar for each year
20162025
Free cash flow margin
−281.5%
2025 · hover or tap a bar for each year
20162025
Asset turnover+178.4%
0.12
2025 · hover or tap a bar for each year
20162025
ABUS per-share figures Results divided by the shares outstanding at year-end.
Revenue per share+121.1%
$0.07
2025 · hover or tap a bar for each year
20162025
Earnings per share
−$0.17
2025 · hover or tap a bar for each year
20162025
Free cash flow per share
−$0.21
2025 · hover or tap a bar for each year
20162025
Book value per share−23.8%
$0.40
2025 · hover or tap a bar for each year
20162025
Shares outstanding+3.2%
191.6M
2025 · hover or tap a bar for each year
20162025
ABUS financial health Debt, liquidity and how easily interest is covered.
Debt / equity−13.0%
0.05
2025 · hover or tap a bar for each year
20162025
Net debt+$29.2M
−$87.3M
2025 · hover or tap a bar for each year
20162025
Current ratio+92.9%
15.73
2025 · hover or tap a bar for each year
20162025
Interest coverage
-278.9
2025 · hover or tap a bar for each year
20162025
Debt / assets−4.7%
0.04
2025 · hover or tap a bar for each year
20162025
ABUS efficiency & capital use Working capital cycle and where the cash goes.
Days sales outstanding−70 days
54 days
2025 · hover or tap a bar for each year
20162025
Days payables outstanding+1,022 days
1,754 days
2025 · hover or tap a bar for each year
20162025
Cash conversion cycle−1,092 days
-1,700 days
2025 · hover or tap a bar for each year
20162025
Capex / revenue−2.9 pts
0.0%
2025 · hover or tap a bar for each year
20162025
ABUS valuation history
Fiscal year-endToday10-year median
ABUS returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
ABUS debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
ABUS cash returned to shareholders
DividendsBuybacksFree cash flow
ABUS price vs earnings per share
Share price at year-endEPS (right axis)
ABUS key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $921.6M | $606.9M | $414.9M | $351.7M | $413.3M | $269.2M | $158.7M | $211.8M | $276.4M | $130.0M |
| Enterprise value | $834.3M | $490.4M | $297.6M | $217.3M | $276.9M | $168.5M | $71.2M | $87.2M | $167.9M | $18.1M |
| Price / sales | 65.4 | 98.4 | 22.9 | 9.0 | 37.6 | 38.9 | 26.4 | 35.9 | 25.8 | 86.7 |
| Price / book | 12.0 | 6.2 | 3.9 | 2.6 | 2.4 | 2.6 | 2.2 | 1.1 | 1.5 | 0.6 |
| EV / sales | 59.2 | 79.5 | 16.4 | 5.6 | 25.2 | 24.4 | 11.9 | 14.8 | 15.7 | 12.1 |
| Earnings yield | −3.6% | −11.5% | −17.6% | −19.7% | −18.4% | −23.7% | −96.9% | −27.0% | −30.5% | −295.5% |
| Free cash flow yield | −4.3% | −10.7% | −21.0% | −10.2% | −16.5% | −19.2% | −45.1% | −32.6% | −20.2% | −47.6% |
| Dividend yield | — | — | — | — | 2.9% | 4.5% | 7.0% | 4.8% | 0.0% | 0.0% |
| Shareholder yield (dividends + buybacks) | — | — | — | 0.0% | 2.9% | 4.5% | 7.0% | 4.8% | 0.0% | 0.0% |
| Share price at fiscal year-end | $4.81 | $3.27 | $2.50 | $2.33 | $3.89 | $3.55 | $2.78 | $3.83 | $5.05 | $2.45 |
| Per share | ||||||||||
| Revenue per share | $0.07 | $0.03 | $0.11 | $0.26 | $0.10 | $0.09 | $0.11 | $0.11 | $0.20 | $0.03 |
| Earnings per share | −$0.17 | −$0.38 | −$0.44 | −$0.46 | −$0.72 | −$0.84 | −$2.69 | −$1.03 | −$1.54 | −$7.24 |
| Operating cash flow per share | −$0.21 | −$0.35 | −$0.52 | −$0.23 | −$0.64 | −$0.68 | −$1.24 | −$1.23 | −$0.89 | −$1.09 |
| Free cash flow per share | −$0.21 | −$0.35 | −$0.52 | −$0.24 | −$0.64 | −$0.68 | −$1.25 | −$1.25 | −$1.02 | −$1.17 |
| Cash per share | $0.48 | $0.66 | $0.76 | $0.97 | $1.46 | $1.63 | $1.59 | $2.25 | $2.31 | $2.46 |
| Book value per share | $0.40 | $0.52 | $0.64 | $0.91 | $1.59 | $1.34 | $1.27 | $3.62 | $3.33 | $3.83 |
| Tangible book value per share | $0.40 | $0.52 | $0.64 | $0.91 | $1.59 | $1.34 | $1.27 | $2.42 | $1.82 | $1.49 |
| Dividends per share | — | — | — | — | $0.11 | $0.16 | $0.20 | $0.18 | $0.00 | $0.00 |
| Capex per share | $0.00 | $0.00 | $0.01 | $0.00 | $0.01 | $0.00 | $0.01 | $0.02 | $0.13 | $0.08 |
| Debt per share | $0.02 | $0.03 | $0.05 | $0.08 | $0.18 | $0.30 | $0.06 | — | $0.33 | $0.35 |
| Shares outstanding | 191.6M | 185.6M | 166.0M | 150.9M | 106.2M | 75.8M | 57.1M | 55.3M | 54.7M | 53.1M |
| Change in shares outstanding | +3.2% | +11.8% | +10.0% | +42.1% | +40.1% | +32.8% | +3.2% | +1.1% | +3.1% | +16.7% |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −38.5% | −68.8% | −60.0% | −45.4% | −56.2% | −73.0% | −112.6% | −29.8% | −43.8% | −102.3% |
| Return on invested capital (ROIC) | — | — | — | −291.1% | −339.0% | — | — | −94.8% | −106.0% | −167.5% |
| Return on assets (ROA) | −29.6% | −50.6% | −42.9% | −34.7% | −44.6% | −52.5% | −92.2% | −24.6% | −32.9% | −77.7% |
| Return on tangible assets | −35.4% | −53.1% | −50.4% | −35.5% | −37.3% | −46.5% | −145.7% | −35.3% | −54.7% | −252.5% |
| Free cash flow margin | −281.5% | — | −479.3% | −91.9% | −622.0% | −747.3% | — | — | −522.1% | — |
| Financial health | ||||||||||
| Total debt | $4.2M | $6.1M | $8.7M | $12.6M | $18.9M | $22.5M | $3.4M | — | $18.0M | $18.7M |
| Cash & short-term investments | $91.5M | $122.6M | $126.0M | $146.9M | $155.3M | $123.3M | $90.8M | $124.6M | $126.4M | $130.5M |
| Net debt | −$87.3M | −$116.5M | −$117.3M | −$134.4M | −$136.4M | −$100.7M | −$87.5M | −$124.6M | −$108.4M | −$111.8M |
| Debt / equity | 0.05 | 0.06 | 0.08 | 0.09 | 0.11 | 0.22 | 0.05 | — | 0.10 | 0.09 |
| Debt / assets | 0.04 | 0.05 | 0.06 | 0.06 | 0.09 | 0.16 | 0.03 | — | 0.08 | 0.07 |
| Current ratio | 15.73 | 8.15 | 5.87 | 4.60 | 14.32 | 13.38 | 11.99 | 11.50 | 10.87 | 12.51 |
| Quick ratio | 15.73 | 8.15 | 5.95 | 4.69 | 14.71 | 13.71 | 11.99 | 11.50 | 10.87 | 12.51 |
| Interest coverage | -278.9 | -557.1 | -170.2 | -37.9 | -25.7 | -14.4 | -68.3 | -449.0 | -424.9 | -353.4 |
| Working capital | $88.5M | $111.7M | $109.5M | $118.3M | $149.4M | $118.2M | $86.0M | $118.0M | $117.5M | $122.0M |
| Invested capital | −$10.7M | −$19.1M | −$11.3M | $2.5M | $33.0M | $1.2M | −$14.7M | $75.6M | $74.1M | $91.2M |
| Tangible asset value | $76.6M | $97.4M | $106.0M | $136.9M | $169.4M | $102.0M | $72.7M | $133.9M | $99.5M | $79.2M |
| Net current asset value | $76.4M | $93.0M | $93.6M | $92.6M | $125.6M | $92.6M | $61.0M | $101.6M | $74.7M | $59.7M |
| Graham net-net per share | $0.39 | $0.49 | $0.53 | $0.58 | $1.12 | $1.15 | $1.03 | $1.77 | $1.32 | $1.09 |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | — | $12.1M | $12.1M | $11.1M | $10.1M | $0 | $0 |
| Share buybacks (net) | — | — | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Capex / revenue | 0.0% | 2.9% | 5.6% | 1.3% | 7.4% | 3.3% | 9.8% | 19.3% | 67.9% | 266.4% |
| Capex / depreciation | 0.00 | 0.13 | 0.72 | 0.36 | 0.46 | 0.12 | 0.29 | 0.52 | 3.58 | 3.66 |
| Stock-based compensation / revenue | 49.4% | 145.6% | 51.3% | 18.4% | 58.5% | 89.1% | 113.1% | 105.8% | 141.3% | 2,610.6% |
| R&D / revenue | 179.2% | 875.7% | 406.3% | 216.3% | 596.1% | 713.6% | 958.3% | 981.4% | 586.0% | 4,086.7% |
| SG&A / revenue | 112.9% | 358.3% | 131.6% | 45.7% | 156.0% | 214.7% | 294.9% | 271.2% | 150.5% | 2,626.7% |
| Efficiency | ||||||||||
| Days sales outstanding | 53.9 | 123.8 | 31.5 | 10.5 | 36.7 | 66.4 | 80.0 | 56.6 | 11.9 | 204.6 |
| Days of inventory on hand | — | — | -11.5 | -936.0 | -788.0 | -24.0 | — | — | — | 3.2 |
| Days payables outstanding | 1,754.1 | 732.5 | 16.7 | 856.1 | 642.1 | 20.7 | 17.7 | 16.3 | 15.1 | 17.3 |
| Cash conversion cycle (days) | -1,700.3 | -608.7 | 3.3 | -1,781.6 | -1,393.4 | 21.7 | 62.3 | 40.3 | -3.2 | 190.5 |
| Receivables turnover | 6.78 | 2.95 | 11.60 | 34.67 | 9.94 | 5.50 | 4.56 | 6.44 | 30.57 | 1.78 |
| Payables turnover | 0.21 | 0.50 | 21.86 | 0.43 | 0.57 | 17.61 | 20.61 | 22.36 | 24.11 | 21.05 |
| Inventory turnover | — | — | — | — | — | — | — | — | — | 114.79 |
| Asset turnover | 0.12 | 0.04 | 0.11 | 0.20 | 0.06 | 0.06 | 0.04 | 0.03 | 0.04 | 0.00 |
| Average receivables | $2.1M | $2.1M | $1.6M | $1.1M | $1.1M | $1.3M | $1.3M | $915,500 | $350,000 | $841,000 |
| Average payables | $1.7M | $2.8M | $3.4M | $3.3M | $3.1M | $2.7M | $2.8M | $2.6M | $2.6M | $2.9M |
| Average inventory | — | — | −$2.3M | −$3.7M | −$3.8M | −$3.1M | — | — | $0 | $534,000 |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 29.1% | 35.0% | 44.9% |
Computed from ABUS's annual financial statements (latest annual report filed March 23, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
ABUS valuation and financial ratios
Based on the latest twelve months, the trailing P/E is 5.3 and the forward P/E is 10.2. Arbutus Biopharma earned a return on equity of −38.5% in fiscal 2025. It ended the year with $4.2 million of debt and $91.5 million in cash and short-term investments, a net cash position of $87.3 million. The share count rose 261.2% from 53.1M to 191.6M over 9 years.
See the ABUS income statement, the ABUS chart for price history, or the ABUS stock overview for the latest quote and news.
ABUS key metrics FAQ
What is Arbutus Biopharma's P/E ratio?
Arbutus Biopharma's trailing P/E ratio is 5.3 based on the last twelve months of earnings (as of October 17, 2026), and its forward P/E is 10.2. At the end of fiscal 2025 it was —.
What is Arbutus Biopharma's return on equity?
Arbutus Biopharma's return on equity (ROE) was −38.5% in fiscal 2025: net income of -$33.5 million on average shareholders' equity of $87.0 million.
How much debt does Arbutus Biopharma have?
Arbutus Biopharma had total debt of $4.2 million at the end of fiscal 2025, a debt-to-equity ratio of 0.05 and more cash than debt.
What is Arbutus Biopharma's free cash flow yield?
Arbutus Biopharma generated -$39.6 million of free cash flow in fiscal 2025, a free cash flow yield of −4.3% on its market value at year-end ($921.6 million).
What is Arbutus Biopharma's current ratio?
Arbutus Biopharma's current ratio was 15.73 at the end of fiscal 2025: current assets were 15.73 times current liabilities.